[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 17, 1970

Medical News

JAMA. 1970;213(7):1109-1122. doi:10.1001/jama.1970.03170330001001

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

Mass production of vaccine for meningitis delayed  Since the Army-developed (and Army-tested) vaccine has no license manufacturers appear reluctant to produce the vaccine in quantityThe new vaccine for Type C meningococcal meningitis is in a sort of administrative and scientific limbo. It may be some time before large stocks of a licensed product are available.The Army began general, but limited, use of the vaccine several months ago. (JAMAMedical News211:1107 [Feb 16] 1970). The vaccine is, quite rightly, a source of Army pride. It was developed at the Army's Walter Reed Institute of Research, Washington, DC, by a team led by Malcolm Artenstein, MD, chief developer of the rubella vaccine. A series of laboratory and large-scale field trials have been successful. The vaccine produced a ten-fold reduction in the incidence of the disease, an antibody response in more than 90% of recipients, and virtually no side

×